ESC Premium Access

Optimising P2Y12 inhibition in real world clinical practice: clinical outcomes of prasugrel and ticagrelor.

Topic: Thrombosis and platelets
Sponsored by Daiichi Sankyo Europe GmbH

Congress Session

About the speaker

Professor J Wouter Jukema

Leiden University Medical Centre, Leiden (Netherlands (The))
16 presentations
0 follower

3 more presentations in this session

Welcome & introduction: Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

How to apply guidelines to clinical practice.

Speaker: Professor A. Schaefer (Hannover, DE)

Thumbnail

Discussion – Summary and closing remarks: potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speaker: Professor K. Huber (Vienna, AT)

Thumbnail

Access the full session

Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speakers: Professor J. Jukema, Professor K. Huber, Professor A. Schaefer, Professor K. Huber
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk